Wednesday 19th of January 2022 12:52:08 PM
Following agreement with Thermo Fisher, Oncocyte shares plunge 24%
Gearstd/iStock via Getty Images
- Following an after-the-closing bell announcement yesterday of a development and co-marketing agreement with Thermo Fisher Scientific (TMO +0.7%), shares of Oncocyte (OCX -23.5%) fell sharply today.
- The agreement involves in vitro diagnostic assays on Thermo Fisher Scientific’s Ion Torren Genexus System. Oncocyte has rights to develop future companion diagnostics on the Genexus System.
- Oncocyte was up about 1% year to date before today's decline.
- Last month, the company said one of its diagnostic tests is able to predict a patient's response to breast cancer immunotherapy.